Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

About Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals logoRitter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $7.41 million
  • Outstanding Shares: 14,756,000
Average Prices:
  • 50 Day Moving Avg: $0.55
  • 200 Day Moving Avg: $0.55
  • 52 Week Range: $0.48 - $3.75
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.85
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.20 per share
  • Price / Book: 2.46
Profitability:
  • EBIDTA: ($14,790,000.00)
  • Return on Equity: -399.81%
  • Return on Assets: -218.40%
Debt:
  • Current Ratio: 2.07%
  • Quick Ratio: 2.07%
Misc:
  • Average Volume: 141,843 shs.
  • Beta: 0.65
  • Short Ratio: 2.76
 

Frequently Asked Questions for Ritter Pharmaceuticals (NASDAQ:RTTR)

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) announced its earnings results on Monday, August, 7th. The company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.00. View Ritter Pharmaceuticals' Earnings History.

Where is Ritter Pharmaceuticals' stock going? Where will Ritter Pharmaceuticals' stock price be in 2017?

5 brokerages have issued 12 month price objectives for Ritter Pharmaceuticals' stock. Their predictions range from $1.50 to $9.00. On average, they anticipate Ritter Pharmaceuticals' share price to reach $5.70 in the next year. View Analyst Ratings for Ritter Pharmaceuticals.

Who are some of Ritter Pharmaceuticals' key competitors?

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:

  • Ira E. Ritter, Executive Chairman of the Board, Chief Strategic Officer
  • Michael D. Step, Chief Executive Officer, Director
  • Ellen Mochizuki, Vice President - Finance
  • Andrew J. Ritter, President, Founder, Director
  • Noah J. Doyle, Independent Director
  • Matthew W. Foehr, Independent Director
  • Paul V. Maier, Independent Director
  • William M. Merino Ph.D., Independent Director
  • Gerald T. Proehl, Independent Director

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

How do I buy Ritter Pharmaceuticals stock?

Shares of Ritter Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of Ritter Pharmaceuticals stock can currently be purchased for approximately $0.50.


MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ritter Pharmaceuticals (NASDAQ:RTTR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $5.70 (1,035.01% upside)

Analysts' Ratings History for Ritter Pharmaceuticals (NASDAQ:RTTR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Chardan CapitalLower Price TargetBuy -> Buy$3.50 -> $1.50MediumView Rating Details
8/4/2017Maxim GroupReiterated RatingHoldLowView Rating Details
3/7/2017AegisReiterated RatingBuyMediumView Rating Details
1/4/2017Rodman & RenshawInitiated CoverageBuy$7.00N/AView Rating Details
12/12/2016Roth CapitalInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Ritter Pharmaceuticals (NASDAQ:RTTR)
Earnings by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Earnings History by Quarter for Ritter Pharmaceuticals (NASDAQ RTTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.15)($0.14)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.38)($0.14)ViewN/AView Earnings Details
2/27/2017Q4 2016($0.35)($0.74)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.50)($0.41)ViewN/AView Earnings Details
8/8/2016Q216($0.34)($0.48)ViewN/AView Earnings Details
5/9/2016($0.32)($0.36)ViewN/AView Earnings Details
3/21/2016Q4($0.34)($0.27)ViewN/AView Earnings Details
11/17/2015Q315($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ritter Pharmaceuticals (NASDAQ:RTTR)
Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS

Dividends

Dividend History for Ritter Pharmaceuticals (NASDAQ:RTTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ritter Pharmaceuticals (NASDAQ:RTTR)
Insider Ownership Percentage: 30.40%
Institutional Ownership Percentage: 7.55%
Insider Trades by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Institutional Ownership by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Insider Trades by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Matthew W FoehrDirectorBuy18,000$0.62$11,160.00View SEC Filing  
5/11/2017Michael D StepCEOBuy13,000$0.62$8,060.00View SEC Filing  
2/27/2017Michael D StepCEOBuy10,000$2.65$26,500.00View SEC Filing  
2/22/2016Andrew J RitterMajor ShareholderBuy6,250$1.60$10,000.00View SEC Filing  
1/8/2016Matthew W FoehrDirectorBuy13,000$1.64$21,320.00View SEC Filing  
1/7/2016Michael D StepCEOBuy27,000$1.48$39,960.00View SEC Filing  
6/24/2015Gerald T ProehlDirectorBuy50,000$5.00$250,000.00View SEC Filing  
6/24/2015Javelin Venture Partners, L.P.Major ShareholderBuy800,000$5.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ritter Pharmaceuticals (NASDAQ:RTTR)
Latest Headlines for Ritter Pharmaceuticals (NASDAQ:RTTR)
Source:
DateHeadline
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - September 24 at 2:08 PM
americanbankingnews.com logoZacks: Analysts Anticipate Ritter Pharmaceuticals, Inc. (RTTR) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - September 24 at 12:18 AM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Downgraded by Zacks Investment Research
www.americanbankingnews.com - September 23 at 6:36 AM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - September 16 at 7:18 AM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - September 9 at 8:40 AM
americanbankingnews.com logoZacks Investment Research Downgrades Ritter Pharmaceuticals, Inc. (RTTR) to Hold
www.americanbankingnews.com - September 7 at 8:20 AM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 5 at 9:00 PM
americanbankingnews.com logoFinancial Comparison: Ritter Pharmaceuticals (RTTR) versus Acorda Therapeutics (ACOR)
www.americanbankingnews.com - August 31 at 6:14 AM
americanbankingnews.com logoZacks Investment Research Upgrades Ritter Pharmaceuticals, Inc. (RTTR) to Buy
www.americanbankingnews.com - August 29 at 10:20 AM
streetinsider.com logoRitter Pharmaceuticals (RTTR) Reports Phase 3 Plans Following End of Phase 2 Meeting with FDA on RP-G28 for LI
www.streetinsider.com - August 19 at 7:11 AM
finance.yahoo.com logoRitter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance
finance.yahoo.com - August 19 at 7:11 AM
americanbankingnews.com logo Analysts Anticipate Ritter Pharmaceuticals, Inc. (RTTR) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - August 17 at 6:16 PM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 11 at 11:32 PM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (NASDAQ:RTTR) Posts Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - August 8 at 1:36 PM
americanbankingnews.com logoChardan Capital Trims Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Target Price to $1.50
www.americanbankingnews.com - August 8 at 1:20 PM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (NASDAQ:RTTR) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 8 at 8:50 AM
streetinsider.com logoRitter Pharma (RTTR) Reports FDA to Schedule End-of-Phase 2 Meetings; Granted 3 New Patents for RP-G28 ... - StreetInsider.com
www.streetinsider.com - August 8 at 6:48 AM
feeds.benzinga.com logoRitter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
feeds.benzinga.com - August 7 at 7:16 AM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Rating Reiterated by Maxim Group
www.americanbankingnews.com - August 4 at 3:48 PM
finance.yahoo.com logoRitter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms
finance.yahoo.com - August 4 at 7:46 AM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 8:14 PM
americanbankingnews.com logoMaxim Group Reiterates "Hold" Rating for Ritter Pharmaceuticals, Inc. (RTTR)
www.americanbankingnews.com - July 9 at 6:02 PM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 6 at 10:30 AM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 20 at 8:52 PM
americanbankingnews.com logoRitter Pharmaceuticals, Inc. (RTTR) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - June 12 at 10:24 AM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Short Interest Update
www.americanbankingnews.com - May 28 at 7:12 AM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 26 at 9:05 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 23 at 7:18 AM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Director Matthew W. Foehr Acquires 18,000 Shares
www.americanbankingnews.com - May 18 at 4:54 PM
americanbankingnews.com logo-$0.27 Earnings Per Share Expected for Ritter Pharmaceuticals Inc (RTTR) This Quarter
www.americanbankingnews.com - May 15 at 10:30 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Releases Quarterly Earnings Results, Beats Expectations By $0.24 EPS
www.americanbankingnews.com - May 10 at 4:56 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Rating Reiterated by Maxim Group
www.americanbankingnews.com - May 9 at 11:36 PM
nasdaq.com logoRitter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-
www.nasdaq.com - May 4 at 12:21 AM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Getting Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 1:03 AM
streetinsider.com logoRitter Pharma (RTTR) Announces New Patents for its Lactose Intolerance Treatment, RP-G28; Provides an Update on ... - StreetInsider.com
www.streetinsider.com - May 2 at 5:27 PM
finance.yahoo.com logoRitter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3
finance.yahoo.com - May 2 at 5:27 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 1 at 10:32 PM
feeds.benzinga.com logoExclusive: Ritter Pharmaceuticals CEO Talks Stock Scare, Indication Niche
feeds.benzinga.com - April 28 at 10:42 AM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Given News Sentiment Score of 0.07
www.americanbankingnews.com - April 27 at 11:26 PM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Receiving Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - April 24 at 11:20 AM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Given News Impact Score of 0.37
www.americanbankingnews.com - April 18 at 5:48 PM
americanbankingnews.com logoRitter Pharmaceuticals (RTTR) Earning Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 14 at 10:23 PM
streetinsider.com logoRitter Pharma (RTTR) Says FDA Agrees to Schedule End of Phase 2 Meeting - StreetInsider.com
www.streetinsider.com - April 12 at 6:22 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Receives "Hold" Rating from Maxim Group
www.americanbankingnews.com - April 12 at 4:36 PM
finance.yahoo.com logoRitter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities
finance.yahoo.com - April 12 at 1:21 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Price Target Cut to $3.50 by Analysts at Chardan Capital
www.americanbankingnews.com - April 5 at 10:16 AM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 6:09 PM
americanbankingnews.com logoRitter Pharmaceuticals Inc (RTTR) PT Lowered to $3.50
www.americanbankingnews.com - March 30 at 8:53 AM
baystreet.ca logoRitter Pharmaceuticals (RTTR) Flails on Study Results
www.baystreet.ca - March 29 at 9:25 PM
finance.yahoo.com logoRitter Pharmaceuticals downgraded by Maxim Group
finance.yahoo.com - March 29 at 9:25 PM

Social

Chart

Ritter Pharmaceuticals (RTTR) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff